Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) (COVID-19) (REALIST)

• ClinicalTrials.gov Identifier: NCT03042143
• Recruitment Status: Active, not recruiting
• First Posted: February 3, 2017
• Last Update Posted: August 20, 2021
• Sponsor: Belfast Health and Social Care Trust
• Collaborators: Queen's University, Belfast; Northern Ireland Clinical Trials Unit; NHS Blood and Transplant
• Information provided by (Responsible Party): Professor Danny McAuley, Belfast Health and Social Care Trust

No Study Results Posted on ClinicalTrials.gov for this Study

• Recruitment Status: Active, not recruiting
• Estimated Primary Completion Date: July 2022
• Estimated Study Completion Date: March 2024

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Gorman E, Shankar-Hari M, Hopkins P, Tunnicliffe WS, Perkins GD, Silversides J, McGuigan P, Krasnodembskaya A, Jackson C, Boyle R, McFerran J, McDowell C, Campbell C, McFarland M, Smythe J, Thompson J, Williams B, Curley G, Laffey JG, Clarke M, McAuley DF, O'Kane CM. Repair of acute respiratory distress syndrome by stromal cell administration (REALIST) trial: A phase 1 trial. EClinicalMedicine. 2021 Oct 24;41:101167. doi: 10.1016/j.eclinm.2021.101167. eCollection 2021 Nov.

Gorman E, Shankar-Hari M, Hopkins P, Tunnicliffe WS, Perkins GD, Silversides J, McGuigan P, Jackson C, Boyle R, McFerran J, McDowell C, Campbell C, McFarland M, Smythe J, Thompson J, Williams B, Curley G, Laffey JG, Clarke M, O'Kane C, McAuley DF. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial. Trials. 2020 Jun 3;21(1):462. doi: 10.1186/s13063-020-04416-w.